Preparation method of rosaxostat intermediate
By adopting mild reaction conditions and simplified steps in the synthesis of rosalstat raw materials, the problems of long and high cost in the prior art are solved, and the efficient and low-cost preparation of rosalstat intermediates are achieved. Suitable for industrial production.
Patent Information
- Application Number
- CN202411006315.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-15
AI Technical Summary
The existing rosalstat raw material synthesis route has long steps, low yield and high production costs, and is not suitable for large-scale commercial production.
Using 4-phenoxybenzoic acid as the starting material, chlorination with malonate under an aprotic solvent, followed by halogenation, ammonization and acetamation, and radiated rosa was prepared gradually by mild reaction conditions. The sitar intermediate reduces the use of high temperature and high pressure.
The preparation of rosalstat intermediates with cheap and easy-to-get raw materials, mild reaction conditions and high yields is achieved. It is suitable for industrial production and reduces production costs.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention relates to a method for preparing a rosuvastatin intermediate, and belongs to the technical field of pharmaceutical preparation and production. Background Art
[0002] Roxadustat, whose chemical name is [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid, was developed by FibroGen in the United States. It is the world's first oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor, which can induce erythropoiesis and treat renal anemia. Roxadustat is approved for the treatment of anemia in CKD dialysis patients, including hemodialysis and peritoneal dialysis patients.
[0003]
[0004] Renal anemia is a very common disease in patients with chronic kidney disease (CKD). The morbidity and mortality rates are very high for both dialysis and non-dialysis CKD patients. CKD can occur at any age, but it is more common in the elderly. The current anti-anemia therapy for CKD patients is mainly injection of erythropoiesis stimulating agents (ESAs), but ESAs have an increased risk of adverse cardiovascular reactions. Roxadustat is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that can provide CKD patients with a more convenient (oral) and safer treatment option. Therefore, a roxadustat production process with low production cost, high product yield, good product quality and optimized environment has been developed to reduce medical costs for kidney patients.
[0005] At present, the synthesis methods of rosuvastatin API are reported as follows:
[0006] The original research patent WO2004108681A1 (the domestic patent of the same group CN103145616B, etc.) is a nitrogen-containing heteroaryl compound and its use in increasing endogenous erythropoietin. The original research route is to use 3,4-dicyanonitrobenzene as the starting material, and carry out phenol etherification reaction, cyano hydrolysis reaction, glycine amidation reaction, esterification reaction, cyclization reaction, bromination reaction, hydrolysis reaction, methylation reaction, hydroxyl protection reaction, ester hydrolysis reaction, glycine condensation reaction and deprotection reaction and other multi-step reactions to obtain rosastat API.
[0007]
[0008] This route has long steps, low yield and high production cost, and is therefore not conducive to large-scale commercial production.
[0009] In addition, Yuanyan Company has a method for preparing isoquinoline compounds in patent WO2014014834A1 (domestic patent CN103435546B, etc.). It optimizes and improves the original synthesis route. The optimized route uses 2-bromophthalide as the starting material, and undergoes etherification reaction, ring opening and chlorination reaction, glycine ester condensation, ester condensation cyclization, aromatic ring alkylation, amino substitution, reductive alkylation, and glycine amide ester condensation to obtain rosuvastatin.
[0010]
[0011] This route has 8 chemical reactions, and there are too many reaction steps, which leads to a lower overall yield and excessive production costs, which is not conducive to industrial commercial production.
[0012] CN106478504B (Shanghai Xunhe Pharmaceutical Technology Co., Ltd.), a method for preparing Roxadustat intermediates, the route uses m-bromoacetophenone as the starting material, undergoes phenol etherification reaction, hydrochloric acid hydroxylation and sodium borohydride reduction amination reaction, 2-carbonylmalonate generates Schiff base, and finally cyclizes to obtain the Roxadustat intermediate 4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinecarboxylate.
[0013]
[0014] The raw materials used in this synthetic route are relatively expensive. In addition, the cyclization reaction conditions are relatively harsh, the selectivity is poor, and isomers are easily produced, resulting in low product yields and ultimately increased product costs. Therefore, it is not suitable for large-scale production.
[0015] CN111499572A (Anhui Qingyun Pharmaceutical Co., Ltd.), a method for preparing a rosuvastatin intermediate, the synthetic route requires 3-(4-phenoxyphenyl) carbonyl propionate as a starting material, undergoes nitrite amination reaction, palladium carbon reduction of hydroxylamine, acetic anhydride amidation reaction, and finally obtains the intermediate 4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinecarboxylate through a closed ring.
[0016]
[0017] This synthetic route has fewer steps and the starting raw materials are cheap, but the process requires a palladium-carbon hydrogenation reaction after nitrite amination, and the operating conditions are relatively harsh, so it is not suitable for industrial production.
[0018] Therefore, if a low-cost intermediate 2-acetylamino-3-oxo-3-(4-phenoxyphenyl)propionic acid ethyl ester is prepared, the above method can be referred to to prepare low-cost rosuvastatin:
[0019]
[0020] Based on the above literature, there are not many synthetic routes for rosuvastatin API at present. In addition, most of the existing routes are relatively long, resulting in lower product yields and increased production costs, making them unsuitable for industrial production. Some routes are improperly selected, resulting in more by-products in the reaction, or some synthetic routes have harsh production conditions, which are also not conducive to industrial production. Therefore, developing a synthetic process route for rosuvastatin API with moderate reaction routes, mild reaction conditions, high product yields in each step, good quality, and green environmental protection will be beneficial to the commercialization of rosuvastatin, bringing better quality and lower-priced products to kidney patients, and also contributing to society. Summary of the invention
[0021] The purpose of the present invention is to provide a method for preparing a rosuvastatin intermediate to solve the above technical problems.
[0022] In order to achieve the above object, the technical solution adopted by the present invention is:
[0023] A method for preparing a rosuvastatin intermediate, the synthetic route is as follows:
[0024]
[0025] The specific steps include:
[0026] (1) Using 4-phenoxybenzoic acid as a starting material, chlorination and malonate reaction were carried out in an aprotic solvent to prepare intermediate 1;
[0027] (2) Intermediate 1 undergoes a halogenation reaction to generate intermediate 2, wherein R1 is a halogen atom;
[0028] (3) intermediate 2 is subjected to an amination reaction to obtain intermediate 3 hydrochloride, wherein the ammonia source can be liquid ammonia, an alcohol solution of ammonia, an aqueous solution of ammonia, or phthalimide or its sodium salt or potassium salt;
[0029] (4) Intermediate 3 reacts with acetic anhydride or acetyl chloride to obtain acetamide intermediate 4.
[0030] A further improvement of the technical solution of the present invention is that in the preparation method of intermediate 1, 4-phenoxybenzoic acid is used as the starting material, wherein the malonate ester can be diethyl malonate, dimethyl malonate, potassium salt of monoethyl malonate, or sodium salt of monoethyl malonate; preferably potassium salt of monoethyl malonate.
[0031] The technical solution of the present invention is further improved as follows: in step 1, triethylamine, diisopropylethylamine, sodium carbonate, potassium carbonate, one of these weak bases, preferably triethylamine or diisopropylethylamine, is added; in step 1, anhydrous magnesium chloride is added as a catalytic reaction reagent.
[0032] A further improvement of the technical solution of the present invention is as follows: in step 2, in the preparation method of intermediate 2, the halogen substitution reaction atom can be a chlorine atom, a bromine atom and an iodine atom; preferably, a bromine atom is used as the substitution atom.
[0033] A further improvement of the technical solution of the present invention is that the solvent used in the halogenation reaction in step 2 can be a protic solvent or an aprotic solvent, preferably dichloromethane, chloroform, ethyl acetate, DMF, DMSO, ethanol, isopropanol, water, and the like.
[0034] A further improvement of the technical solution of the present invention is that in step 3, the alkylamines added in the amino substitution reaction may be liquid ammonia, ammonia gas, ammonia water, potassium phthalimide, etc. as amine sources.
[0035] A further improvement of the technical solution of the present invention is that the solvent used for the amino substitution reaction in step 3 can be a protic solvent or an aprotic solvent, preferably tetrahydrofuran, dichloromethane, chloroform, DMF, DMSO, ethanol, isopropanol, water, and the like.
[0036] A further improvement of the technical solution of the present invention is that in the acetamidoation reaction of step 4, acetyl chloride, acetic anhydride or acetic acid is used as an acetyl group providing reagent.
[0037] A further improvement of the technical solution of the present invention is that the solvent used in the acetamido reaction of step 4 can be a non-polar or polar organic solvent, preferably dichloromethane, chloroform, ethyl acetate, acetonitrile, tetrahydrofuran, DMF, DMSO, etc.
[0038] A further improvement of the technical solution of the present invention is that the preparation process of each intermediate in step 1, step 2, step 3 and step 4 also includes post-reaction quenching, extraction, recrystallization, and refining, which are post-treatment steps.
[0039] Due to the adoption of the above technical solution, the technical effects achieved by the present invention are as follows:
[0040] The raw materials and auxiliary materials used in the present invention are all commercially available, the raw materials and auxiliary materials used in the process synthesis method are all market commodities, the raw materials are cheap and easy to obtain, the reaction conditions of the present invention are mild, the yield is high, and harsh reaction conditions such as high temperature and high pressure are not used, which is suitable for industrial and commercial production. The product produced by the method of the present invention has good quality. DETAILED DESCRIPTION
[0041] In order to make the technical means, creative features, objectives and effects achieved by the present invention easy to understand, the present invention is further explained below in conjunction with specific implementation methods.
[0042] The invention discloses a method for preparing a rosuvastatin intermediate. The method prepares the rosuvastatin intermediate through a completely new process, and then prepares rosuvastatin.
[0043] In the technical scheme, the rosuvastatin intermediate is prepared, including intermediate 1, intermediate 2, intermediate 3 and intermediate 4, intermediate 4 is reacted to obtain intermediate 5, and intermediate 5 is reacted to obtain rosuvastatin.
[0044] The key point of this technical solution is to use raw materials to prepare intermediate 4 through intermediate 1, intermediate 2 and intermediate 3 in sequence. The synthesis route is as follows:
[0045]
[0046] The specific steps include:
[0047] (1) Using 4-phenoxybenzoic acid as the starting material, the intermediate 1 is prepared by reacting 4-phenoxybenzoic acid with malonic acid ester in an aprotic solvent.
[0048] Wherein, the malonate can be diethyl malonate or dimethyl malonate or monoethyl malonate potassium salt, or monoethyl malonate sodium salt; preferably monoethyl malonate potassium salt. Triethylamine, diisopropylethylamine, sodium carbonate, potassium carbonate, one of these weak bases, preferably triethylamine or diisopropylethylamine, is added to the reaction. Anhydrous magnesium chloride is also required to be added as a catalytic reaction reagent. The reaction solvent is mostly selected from dichloromethane, tetrahydrofuran, chloroform, etc., preferably dichloromethane.
[0049] Furthermore, it is preferred that the molar ratio of 4-phenyloxybenzoic acid to potassium monoethyl malonate is 1.00:(0.90-2.00), preferably 1.00:(1.00-1.50), and most preferably 1.00:(1.10-1.30).
[0050] The preferred reaction process is as follows: 4-phenoxybenzoic acid is used as the starting material, 4-phenoxybenzoyl chloride is generated by chlorination, and then added dropwise to a reaction solution of malonate, magnesium chloride and triethylamine as a base, and then the intermediate 2 is obtained by post-treatment acidification and other conditions. The preferred reaction equation of step 1 is as follows:
[0051]
[0052] (2) Intermediate 1 undergoes a halogenation reaction to generate intermediate 2, wherein R1 is a halogen atom. The halogen substitution atom may be a chlorine atom, a bromine atom, or an iodine atom; preferably, a bromine atom is used as the substitution atom.
[0053] In the reaction, the halogenating agent can be NCS, NBS, NIS, chlorine, bromine, iodine or their corresponding salts, wherein bromine and NBS are preferably used, and NBS is the most preferred. The solvent used for the bromination reaction of intermediate 1 can be a protic solvent or an aprotic solvent, such as dichloromethane, chloroform, ethyl acetate, DMF, DMSO, ethanol, isopropanol, water and the like, wherein dichloromethane, chloroform, ethyl acetate, acetonitrile and the like are preferred, and dichloromethane, chloroform and the like are most preferred.
[0054] Further, specifically and preferentially, the molar ratio of intermediate 1 to halogenation reaction can be 1.00:(0.90-3.00), preferably 1.00:(1.00-2.00), and most preferably 1.00:(1.05-1.50). The reaction temperature of the halogenation reaction is -30-100°C, preferably 0-60°C, and most preferably 10-30°C.
[0055] The preferred reaction process is as follows: Intermediate 1 reacts with a bromination reagent in an organic solvent to generate Intermediate 2. The preferred reaction equation is as follows:
[0056]
[0057] (3) Intermediate 2 is subjected to an ammoniation reaction to obtain intermediate 3 hydrochloride, wherein the ammonia source may be liquid ammonia, an alcoholic solution of ammonia, or an aqueous solution of ammonia, or phthalimide or its sodium salt potassium salt. Specifically, liquid ammonia, ammonia gas, ammonia water, potassium phthalimide, and these alkylamines may be added as amine sources in the amino substitution reaction. Among them, organic solvent reagents of ammonia and potassium (sodium) phthalimide are preferred, and potassium (sodium) phthalimide is most preferred. The solvent used in the amino substitution reaction may be a protic solvent or an aprotic solvent, preferably tetrahydrofuran, dichloromethane, chloroform, DMF, DMSO, ethanol, isopropanol, water, and these solvents. Among them, the preferred solvent is an organic solvent such as ethanol, DMF, DMSO, and the most preferred solvent is ethanol and DMF.
[0058] Furthermore, in the ammonia substitution reaction, preferably, the molar ratio of the intermediate 2 to the amine reagent is 1.00:(0.90-2.00), preferably 1.00:(1.00-1.60), and most preferably 1.00:(1.05-1.20).
[0059] The preferred reaction process is as follows: Intermediate 2 reacts with an amine reagent in an organic solvent to generate intermediate 3. The preferred reaction equation is as follows:
[0060]
[0061] (4), intermediate 3 reacts with acetic anhydride or acetyl chloride to obtain acetamide intermediate 4 compound. Wherein, the acetyl group can be acetyl chloride, acetic anhydride or acetic acid as the reagent for providing the acetyl group, wherein acetyl chloride or acetic anhydride is preferred. In this step, the acid binding agent used in the acetamide reaction can be an organic base such as triethylamine, diisopropylethylamine, etc., or an inorganic base such as potassium carbonate, sodium carbonate, etc., wherein triethylamine and diisopropylethylamine are preferably used as acid binding agents. The solvent used in the acetamide reaction is an aprotic organic solvent such as dichloromethane, chloroform, tetrahydrofuran, ethyl acetate, DMF, acetonitrile, etc. as the solvent, wherein dichloromethane, chloroform, etc. are preferably used as the reaction solvent.
[0062]
[0063] Further, preferably, the molar ratio of intermediate 3 to acetyl chloride is 1.00:(0.90-2.00), preferably 1.00:(1.00-1.60), and most preferably 1.00:(1.10-1.30). The temperature for the reaction of acetamide is -10-80°C, preferably 0-40°C, and most preferably 0-30°C.
[0064] In the preparation process of each intermediate in the above step 1, step 2, step 3 and step 4, the above preparation process is the process of the main reaction. After the reaction solution is obtained by the main reaction, it is also necessary to carry out post-reaction quenching, extraction, recrystallization, purification and other post-treatment steps.
[0065] The positive progressive effect of the present invention is that the raw materials and raw materials used in the present invention are all commercially available, the raw materials used in the process synthesis method are all bulk commodities in the market, the raw materials are cheap and easy to obtain, the reaction conditions of the present invention are mild, the yield is high, and harsh reaction conditions such as high temperature and high pressure are not used, so it is suitable for industrial production.
[0066] The following are specific embodiments
[0067] Example 1: Preparation of Intermediate 1 (3-oxo-3-(4-phenoxyphenyl)propionic acid ethyl ester)
[0068] Weigh 20.00 g (1.00 eq) of 4-phenoxybenzoic acid and add it to 60 ml of dichloromethane. Add 0.10 g of N,N-dimethylformamide, and dropwise add 16.66 g of thionyl chloride under stirring. After the addition is complete, reflux for 6 hours, concentrate the dichloromethane under reduced pressure, and add 40 ml of ethyl acetate to dissolve it for later use.
[0069] Weigh 23.84 kg (1.50 eq) of potassium ethyl malonate and add it to 80 ml of ethyl acetate, add 14.22 g (1.60 eq) of anhydrous magnesium chloride, and add 17.01 g (1.80 eq) of triethylamine dropwise while stirring. After the addition is complete, stir for 3 hours, then lower the temperature to 0-10°C, then add 17.01 g (1.80 eq) of triethylamine, and add the above-prepared 4-phenoxybenzoyl chloride dropwise while stirring. After the addition is complete, raise the temperature to 20-30°C and stir for 4 hours. After the reaction is complete, add 80 ml of water to the system, adjust the pH value to 3-4 with concentrated hydrochloric acid while stirring, separate the aqueous layer after stirring, wash the ethyl acetate once with 50 ml of saturated brine, dry the ethyl acetate layer with sodium sulfate, filter and concentrate under reduced pressure to obtain ethyl acetate 24.81 g (yield: 93.47%) of light yellow oil, MS (ESI, m / z): 285.1 [M+1 + ],1HNMR(400Hz,CDCl 3 , δ): 1.28 (3H, t), 3.94 (2H, q), 4.24 (2H, s), 6.97 (2H, d), 7.06 (2H, d), 7.10 (1H, dd), 7.38 (2H, dd), 7.91 (2H, d).
[0070] Example 2: Preparation of Intermediate 1 (3-oxo-3-(4-phenoxyphenyl)propionic acid ethyl ester)
[0071] Weigh 2.50 kg of 4-phenoxybenzoic acid and add it to 7.50 L of dichloromethane. Add 12.5 g of N,N-dimethylformamide, and add 2.10 kg of thionyl chloride dropwise while stirring. After the addition is complete, reflux for 6 hours, concentrate the dichloromethane under reduced pressure, add 5.0 L of ethyl acetate, stir and dissolve for later use. Weigh 3.00kg of potassium ethyl malonate and add it to 10.0L of ethyl acetate, add 1.78kg of anhydrous magnesium chloride, and add 2.13kg of triethylamine dropwise while stirring. After the addition is completed, stir for 3 hours, lower the temperature of the reactor to 0-10°C, then add 2.13kg of triethylamine, and add the above-prepared 4-phenoxybenzoyl chloride ethyl acetate solution dropwise while stirring. After the addition is completed, slowly heat it to 20-30°C and stir for 4 hours. After the reaction is completed, add 5.0L of purified water to the system, adjust the pH value to 3-4 with concentrated hydrochloric acid while stirring, separate the water layer after stirring, wash the ethyl acetate once with 5.0L of saturated brine, dry the ethyl acetate layer with sodium sulfate, filter and concentrate under reduced pressure to obtain 3.12kg of ethyl acetate as a light yellow oil (yield: 93.97%).
[0072] Example 3: Preparation of Intermediate 2 (2-bromo-3-oxo-3-(4-phenoxyphenyl)propionic acid ethyl ester)
[0073] 25.00 g (1.00 eq) of intermediate 1 was weighed and added to 150 ml of dichloromethane, 0.50 g of AIBN catalyst was added, and 16.46 g (1.05 eq) of NBS was slowly added under stirring. After adding, the mixture was stirred and refluxed for 6 to 8 hours. After the reaction was completed, 50 ml of purified water, 50 ml of 5% sodium bicarbonate solution, and 50 ml of saturated brine were added to wash once, dried over anhydrous sodium sulfate, and dichloromethane was concentrated. The concentrate was recrystallized from ethyl acetate and n-heptane to obtain 30.07 g (yield 94.15%), MS (ESI, m / z): 363.0 / 365.0 [M+1 + ], 1 HNMR (400 Hz, CDCl 3 , δ): 1.31 (3H, t), 4.22 (2H, q), 5.79 (1H, s), 7.00 (2H, d), 7.09 (2H, d), 7.30 (1H, dd), 7.39 (2H, dd), 7.88 (2H, d).
[0074] Example 4: Pilot preparation of intermediate 2 (ethyl 2-bromo-3-oxo-3-(4-phenoxyphenyl)propionate)
[0075] 3.00 kg of intermediate 1 was weighed and added to a 50 L double-layer glass reactor containing 18.0 L of dichloromethane, 50 g of AIBN catalyst was added, and 2.07 kg of NBS was slowly added under stirring. After adding, the mixture was stirred and refluxed for 6 to 8 hours. After the reaction was completed, the temperature was lowered to 0 to 10 ° C. 6.0 L of purified water, 6.0 L of 5% sodium bicarbonate solution, and 6.0 L of saturated brine were added to wash once, 1.0 kg of anhydrous sodium sulfate was dried, and dichloromethane was concentrated. The concentrate was recrystallized with 3.0 L of ethyl acetate and 9.0 L of n-heptane to obtain 3.67 kg (yield 95.76%).
[0076] Example 5: Preparation of Intermediate 3 (2-amino-3-oxo-3-(4-phenoxyphenyl)propionic acid ethyl ester hydrochloride)
[0077] Weigh the intermediate 2 (30.00 g, 1.00 eq) and add it to 180 ml DMF, stirring and dissolving, cooling to 0-10 ° C, adding potassium phthalimide (16.83 g, 1.10 eq) in batches, heating to 20-30 ° C and stirring for 4-6 hours, after the reaction is completed, add 200 ml of dichloromethane and 100 ml of purified water, stirring and layering, after separating the water layer, wash it once with 100 ml of purified water and once with 100 ml of saturated brine, then reduce the pressure and concentrate the dichloromethane, add 200 ml of ethanol to the concentrate, stirring and dissolving, add 16.73 g of concentrated hydrochloric acid, heat back to 40 ° C, and then add 100 ml of saturated brine to dissolve the dichloromethane. The mixture was stirred for 4 to 6 hours and the temperature was lowered after the reaction was completed, and the mixture was stirred for crystallization. The crystals were filtered out and recrystallized from ethanol to obtain the desired intermediate 3, which weighed 23.47 g (yield: 84.62%). MS (ESI, m / z): 300.1 [M+1+], 1H NMR (400 Hz, d-DMSO, δ): 1.28 (3H, t), 4.20 (2H, q), 4.91 (1H, t), 5.08 (2H, d), 7.07 (2H, d), 7.14 (1H, d), 7.27 (2H, d), 7.38 (2H, dd), 7.87 (2H, d).
[0078] Example 6: Scale-up preparation of intermediate 3 (ethyl 2-amino-3-oxo-3-(4-phenoxyphenyl)propionate hydrochloride)
[0079] Weigh the intermediate 2 (3.5kg, 1.00eq) and add it to 21L of DMF, stirring and dissolving. Cool the reactor to 0-10°C, add potassium phthalimide (1.96kg) in batches, gradually heat it to 20-30°C and stir for 4-6 hours. After the reaction is complete, add 24L of dichloromethane and 10L of purified water, stir and separate, separate the water layer, wash it once with 10L of purified water and once with 10L of saturated brine, and then concentrate the dichloromethane under reduced pressure. After the concentration is complete, add 24L of anhydrous ethanol to the concentrate, stir and dissolve, add 1.95kg of hydrochloric acid, heat and reflux for 4-6 hours. After the reaction is complete, lower the temperature to 0-10°C and stir and crystallize for 2 hours. After the crystals are filtered out, recrystallize them with 10L of ethanol to obtain the desired intermediate 3 weighing 2.79kg (yield: 86.19%).
[0080] Example 7: Preparation of Intermediate 4 (2-acetylamino-3-oxo-3-(4-phenoxyphenyl)propionic acid ethyl ester)
[0081] 20.00 g (1.00 eq) of intermediate 3 was weighed and added to 140 ml of dichloromethane. After stirring, the temperature was lowered to 0-10 ° C. 5.14 g (1.10 eq) of acetyl chloride was added dropwise under stirring. After the addition was completed, 13.86 g (2.30 eq) of triethylamine was added dropwise under temperature control and stirring. After the addition was completed, the temperature was gradually raised to 25-35 ° C. and stirring was continued for 2-3 hours. After the reaction was completed, 70 ml of purified water was added to the system to extract the reaction solution. After separating the water layer, the dichloromethane was washed once with 5% sodium bicarbonate and once with 50 ml of saturated brine. After drying over anhydrous sodium sulfate, the dichloromethane layer was concentrated. The concentrate was recrystallized from ethyl acetate and n-heptane to obtain the desired intermediate 4, weighing 19.61 g (yield: 96.45%), MS (ESI, m / z): 342.1 [M+1 + ], 1 HNMR (400 Hz, CDCl 3 , δ): 1.21 (3H, t), 1.88 (3H, s), 4.16 (2H, q), 6.03 (1H, d), 6.81 (1H, d), 7.06 (2H, d), 7.18 (1H, d), 7.26 (2H, d), 7.39 (2H, dd), 8.10 (2H, d).
[0082] Example 8: Scaled-up preparation of intermediate 4 (ethyl 2-acetylamino-3-oxo-3-(4-phenoxyphenyl)propionate)
[0083] Weigh 2.70kg of intermediate 4 and add it to 19L of dichloromethane. After stirring, lower the temperature in the reactor to 0-10°C, slowly add 0.70kg of acetyl chloride under stirring, and add 1.87kg of triethylamine at 0-10°C after the addition is complete. After the addition is complete, raise the temperature system to 25-35°C, and control the temperature and stir for 2-3 hours. After the reaction is completed, add 8.0kg of purified water to the reactor, stir for 2 minutes, let stand and separate, separate the water layer, wash the dichloromethane with 5kg of 5% sodium bicarbonate and 5kg of saturated brine, dry the dichloromethane with 1kg of anhydrous sodium sulfate, and concentrate under reduced pressure to obtain dichloromethane. Recrystallize the concentrate with 5.4kg of ethyl acetate and 16.2kg of normal heptane, filter out the product, and dry to obtain intermediate 3, weighing 2.68kg (yield 97.64%).
[0084] The above shows and describes the basic principles and main features of the present invention and the advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited to the above embodiments. The above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.
Claims
1. A method for preparing a rosuvastatin intermediate, Features: The synthetic route is as follows, The specific steps include: (1) Using 4-phenoxybenzoic acid as a starting material, chlorination and malonate reaction were carried out in an aprotic solvent to prepare intermediate 1; (2) Intermediate 1 undergoes a halogenation reaction to generate intermediate 2, wherein R1 is a halogen atom; (3) intermediate 2 is subjected to an amination reaction to obtain intermediate 3 hydrochloride, wherein the ammonia source can be liquid ammonia, an alcohol solution of ammonia, an aqueous solution of ammonia, or phthalimide or its sodium salt or potassium salt; (4) Intermediate 3 reacts with acetic anhydride or acetyl chloride to obtain acetamide intermediate 4.
2. A method for preparing a rosuvastatin intermediate according to claim 1, Features: In the preparation method of intermediate 1, 4-phenoxybenzoic acid is used as the starting material, wherein the malonate ester can be diethyl malonate, dimethyl malonate, potassium salt of monoethyl malonate, or sodium salt of monoethyl malonate; preferably potassium salt of monoethyl malonate.
3. A method for preparing a rosuvastatin intermediate according to claim 1, Features: In step 1, triethylamine, diisopropylethylamine, sodium carbonate, potassium carbonate, one of these weak bases, preferably triethylamine or diisopropylethylamine, is added; in step 1, anhydrous magnesium chloride is added as a catalytic reaction reagent.
4. The method for preparing a rosuvastatin intermediate according to claim 1, Features: Step 2 In the preparation method of intermediate 2, the halogen substitution reaction atom can be a chlorine atom, a bromine atom and an iodine atom; preferably, a bromine atom is used as the substitution atom.
5. The method for preparing a rosuvastatin intermediate according to claim 1, Features: The solvent used in the halogenation reaction in step 2 can be a protic solvent or an aprotic solvent, preferably dichloromethane, chloroform, ethyl acetate, DMF, DMSO, ethanol, isopropanol, water, or the like.
6. The method for preparing a rosuvastatin intermediate according to claim 1, Features: In step 3, the alkylamines added in the amino substitution reaction may be liquid ammonia, ammonia gas, ammonia water, potassium phthalimide, etc. as amine sources.
7. The method for preparing a roxadustat intermediate according to claim 1, Features: The solvent used for the amino substitution reaction in step 3 can be a protic solvent or an aprotic solvent, preferably tetrahydrofuran, dichloromethane, chloroform, DMF, DMSO, ethanol, isopropanol, water, or the like.
8. The method for preparing a roxadustat intermediate according to claim 1, Features: In the acetamido reaction of step 4, acetyl chloride, acetic anhydride or acetic acid is used as an acetyl group providing reagent.
9. The method for preparing a roxadustat intermediate according to claim 1, Features: The solvent used in the acetamidation reaction of step 4 can be a non-polar or polar organic solvent, preferably dichloromethane, chloroform, ethyl acetate, acetonitrile, tetrahydrofuran, DMF, DMSO, etc.
10. A method for preparing a roxadustat intermediate according to any one of claims 1 to 9, Features: The preparation process of each intermediate in step 1, step 2, step 3 and step 4 also includes post-reaction quenching, extraction, recrystallization, and purification, which are post-treatment steps.
